A Novel 3 Dimensional Biomaterial for the Production of Multiple Blood Cell Types.
Abstract
Support of wounded personnel is intimately tied to the availability of sufficient quantities of effective blood cells, including conventional red blood cells and platelets and novel therapeutic T lymphocytes and white blood cells. Phase I demonstrated the feasibility of utilizing a novel, biocompatible 3-D device, termed Cellfoam, to support the in vitro production of red blood cells, white blood cells and platelets from human hematopoietic progenitor cells (HPCs). Previous work has shown that Cellfoam enables the long-term, cytokine-free culturing of HPCs while maintaining their multipotency and longevity. In Phase I, HPCs cultured in the presence of selected cytokines were evaluated for cell expansion, phenotype, multipotency and lineage progression over 4 weeks. These studies demonstrated the ability to produce maturing blood progenitor cells from HPCs cultured in Cellfoam. Such culturing enabled cell expansion of up to 100-fold and the acquisition of phenotypic traits consistent with lineage-targeted differentiation. Importantly, cytokine-supplemented HPCs cultures in Cellfoam exhibited enhanced maintenance of immature progenitors relative to controls, corroborating data that Cellfoam offers an enabling environment which selectively preserves immature, multipotent progenitors. Building on this encouraging work, Phase II will develop Cellfoam prototype systems for the first-ever sustained, high-capacity production of functional blood cells from stable HPCs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 30, 1997
- Accession Number
- ADA331374
Entities
People
- Mark J. Pykett